Thomas J Ketas, Devidas Chaturbhuj, Victor M Cruz Portillo, Erik Francomano, Encouse Golden, Sharanya Chandrasekhar, Gargi Debnath, Randy Díaz-Tapia, Anila Yasmeen, Kyle D Kramer, Tarek Munawar, Wilhelm Leconet, Zhen Zhao, Philip J M Brouwer, Melissa M Cushing, Rogier W Sanders, Albert Cupo, Per Johan Klasse, Silvia C Formenti, John P Moore
The approved Pfizer and Moderna mRNA vaccines are well known to induce serum antibody responses to the SARS-CoV-2 Spike (S)-protein. However, their abilities to elicit mucosal immune responses have not been reported. Saliva antibodies represent mucosal responses that may be relevant to how mRNA vaccines prevent oral and nasal SARS-CoV-2 transmission. Here, we describe the outcome of a cross-sectional study on a healthcare worker cohort (WELCOME-NYPH), in which we assessed whether IgM, IgG, and IgA antibodies to the S-protein and its receptor-binding domain (RBD) were present in serum and saliva samples...
2021: Pathogens & Immunity